

National Peptide Receptor Radionuclide Therapy (PRRT) Patient Pathway


PRRT Service in Ireland

Patient Pathway	Roles and Responsibilities	Clinician Responsible for patient's care
Patient identified as potentially eligible for PRRT	Patient to be referred to the national PRRT Tumour conference for discussion	Treating clinician at patient's local hospital
Patient to be discussed at national PRRT Tumour Conference SVUH and decision made on recommended treatment	National PRRT tumour conference including PRRT centre clinicians and treating clinician, as appropriate, to consider patients and decide if to progress for PRRT. Patient prioritisation matrix used to determine if patient has PRRT in SVUH or via TAS	Treating clinician at patient's local hospital together with PRRT centre clinician
Patient to proceed to PRRT ¹ at SVUH or the Treatment Abroad Scheme (TAS) (as capacity is building in SVUH)	PRRT centre to take over care of patient for duration of PRRT	PRRT centre clinician in conjunction with treating clinician at patient's local hospital and/or patients GP

¹ For the treatment of unresectable or metastatic, progressive, well differentiated (Grade 1 and Grade 2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours in adults

National PRRT Patient Pathway	Version: 3
Approval date: March 2023	Review date: March 2026

NEW PRRT PATIENT PATHWAY



National PRRT Patient Pathway	Version: 3
Approval date: March 2023	Review date: March 2026